The particulars: identity confirmation by mass spectrometry · aspartimide formation · a GLP-1 receptor agonist.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
So which one, and on what grounds?
What a useful certificate carries is debatable, but there are certain fields that almost no research-grade certificate includes despite their being standard in pharmaceutical work.
Writing the lot number on your vial in permanent marker is worth doing because it later proves that the certificate traces to your material.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
The relevant detail is that a purity figure to two decimal places with no supporting chromatogram is giving false precision and is a red flag on the same level as spelling errors.
Industry guidance on this topic is consistent because it comes from first principles rather than convention.
My working rule is that a document without a lot number, a method section and a test date is marketing.
edited 23 Mar 2025 by vialroom — tightened the wording; no substantive change
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsA useful certificate has five elements: the lot number, the analytical method, the reported result with units, the date of analysis, and the primary data or a reference to it.
The test date matters because a certificate six months older than the vial is not evidence about your material, it is evidence about what the material was like half a year ago.
The certificate is a snapshot and nothing else — it tells you about the material on one day from one sample of one lot, and extrapolation beyond that requires logic.
Be careful not to over-read this — a certificate that is imperfect is not worthless, it is just a starting point for thought rather than an endpoint.
If the certificate does not trace to your vial, it is not evidence about your vial.
Ask whether the certificate answers the question you are actually asking, because the answer is often no.
Comparison across certificates from different laboratories is almost never valid, even when the material is the same, because the methods are almost never the same.
More usefully, multiple testing on the same lot reported in a single document suggests internal quality control; identical figures across different lots suggests the same certificate reused.
The standards that exist in this space — ICH Q3A, Q3B and various pharmacopoeial chapters — are worth reading once even if nothing you test is obliged to meet them.
The practical summary: check the lot number, ask for the method, and reserve judgement until you have both.
On the detail: the most common trap is reading a certificate as if it were a guarantee when it is actually a single point estimate from a single test.
Batch versus lot is a semantic distinction that determines whether one certificate applies to ten vials or to one, and checking this distinction is worth a minute.
Published inter-laboratory comparisons of the same material routinely find spreads of half a per cent to a full per cent, which sets realistic expectations.
My working rule is that a document without a lot number, a method section and a test date is marketing.
The underlying point is that what makes a certificate useful is not its appearance but whether you could hand it to another laboratory and they would reproduce the result.
A method section that differs markedly from pharmacopoeial standards is either innovative or nonstandard, and distinguishing the two requires expertise.
Pharmacopoeial standards require method validation steps that research-grade certificates almost never claim to meet, and the absence of that claim is itself information.
Worth noting that none of this is medical advice, and a compound sold for research use carries no regulatory approval in any jurisdiction.
If the certificate does not trace to your vial, it is not evidence about your vial.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.